---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122810"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:36:41.798938+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Intellia Q3 net loss $135.7M; cash $944.7M; FDA clears Phase 3 for nex-z polyneuropathy

## Summary
- Net loss $135.7M vs $122.2M YoY; cash $944.7M (down from $1.0B at Dec 31).
- FDA IND clearance for MAGNITUDE-2 Phase 3 trial of nex-z for ATTRv polyneuropathy; enrollment on track by year-end.
- MAGNITUDE Phase 3 (ATTR-CM) enrollment tracking ahead; HAELO Phase 3 (HAE) actively screening.
- Positive Phase 2 data for NTLA-2002: 8/11 patients attack-free after single 50mg dose; no serious AEs.
- On track to dose first patient in NTLA-3001 Phase 1/2 for AATD by year-end.

## SEC filing metadata
- accession: 0000950170-24-122810
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000095017024122810/0000950170-24-122810-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000095017024122810/ntla-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122810
- JSON: https://secwatch.observer/filing/0000950170-24-122810.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122810.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.